{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:49:03Z","timestamp":1782031743947,"version":"3.54.5"},"reference-count":150,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001866","name":"National Research Fund","doi-asserted-by":"publisher","award":["PRIDE21\/16749720\/NEXTIMMUNE2"],"award-info":[{"award-number":["PRIDE21\/16749720\/NEXTIMMUNE2"]}],"id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR219"],"award-info":[{"award-number":["TRR219"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["32290093"],"award-info":[{"award-number":["32290093"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016358","name":"Fondation du P\u00e9lican de Mie et Pierre Hippert-Faber","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015230","name":"Fondation Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189548","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:26:29Z","timestamp":1769819189000},"page":"189548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting store-operated Ca2+ entry as a novel strategy to overcome treatment resistance in melanoma"],"prefix":"10.1016","volume":"1881","author":[{"given":"Daniela Mar\u00eda","family":"Vega Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Niemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Br\u00e9chard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189548_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2026.189548_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0015","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.887366","article-title":"The dark side of melanin secretion in cutaneous melanoma aggressiveness","volume":"12","author":"Caba\u00e7o","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081093","article-title":"The benefit of reactivating p53 under MAPK inhibition on the efficacy of radiotherapy in melanoma","volume":"11","author":"Krayem","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189548_bb0025","doi-asserted-by":"crossref","first-page":"17687","DOI":"10.1038\/s41598-020-74956-3","article-title":"Pathogenic germline variants are associated with poor survival in stage III\/IV melanoma patients","volume":"10","author":"Aoude","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189548_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw135","article-title":"Germline CDKN2A mutation status and survival in familial melanoma cases","volume":"108","author":"Helgadottir","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2026.189548_bb0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189548_bb0040","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.suc.2019.09.005","article-title":"Epidemiology and risk factors of melanoma","volume":"100","author":"Carr","year":"2020","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.bbcan.2026.189548_bb0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbcan.2019.02.002","article-title":"Many ways to resistance: how melanoma cells evade targeted therapies","volume":"1871","author":"Kozar","year":"2019","journal-title":"Biochim. Biophys. Acta BBA Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189548_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081197","article-title":"Targeting oncogenic BRAF: past, present, and future","volume":"11","author":"Zaman","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189548_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189548_bb0065","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty Keith","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189548_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246342","article-title":"Enhancing adoptive cell transfer with combination BRAF-MEK and CDK4\/6 inhibitors in melanoma","volume":"13","author":"Lau","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189548_bb0075","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189548_bb0080","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and Cobimetinib in BRAF -mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189548_bb0085","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114048","article-title":"Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma","volume":"43","author":"Aya","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189548_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153779","article-title":"Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies","volume":"14","author":"Rager","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189548_bb0105","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0110","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbcan.2026.189548_bb0115","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0120","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0125","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of Talimogene Laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0130","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189548_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189548_bb0145","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2217\/fon-2022-0694","article-title":"KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma","volume":"18","author":"Long","year":"2022","journal-title":"Future Oncol. Lond. Engl."},{"key":"10.1016\/j.bbcan.2026.189548_bb0150","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.bbcan.2026.189548_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189548_bb0160","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41416-020-0751-8","article-title":"T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells","volume":"122","author":"Granados","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189548_bb0165","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.3390\/ijms21218274","article-title":"Cellular reprogramming \u2014 a model for melanoma cellular plasticity","volume":"21","author":"Granados","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189548_bb0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2017.18","article-title":"The calcium\u2013cancer signalling nexus","volume":"17","author":"Monteith","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189548_bb0175","series-title":"Membrane Dynamics and Calcium Signaling","first-page":"205","article-title":"Store-operated calcium entry: An historical overview","author":"Putney","year":"2017"},{"key":"10.1016\/j.bbcan.2026.189548_bb0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbrc.2015.02.110","article-title":"Store-operated calcium entry: mechanisms and modulation","volume":"460","author":"Hogan","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189548_bb0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/B978-0-12-407870-3.00010-X","article-title":"The neglected CRAC proteins: Orai2, Orai3, and STIM2","volume":"71","author":"Hoth","year":"2013","journal-title":"Curr. Top. Membr."},{"key":"10.1016\/j.bbcan.2026.189548_bb0190","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1152\/physrev.00020.2014","article-title":"Store-operated calcium channels","volume":"95","author":"Prakriya","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbcan.2026.189548_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0089292","article-title":"Store-operated Ca2+ entry (SOCE) regulates melanoma proliferation and cell migration","volume":"9","author":"Umemura","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189548_bb0200","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1083\/jcb.201407082","article-title":"STIM1- and Orai1-mediated Ca(2+) oscillation orchestrates invadopodium formation and melanoma invasion","volume":"207","author":"Sun","year":"2014","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0205","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/pcmr.12222","article-title":"Inverse regulation of melanoma growth and migration by Orai1\/STIM2-dependent calcium entry","volume":"27","author":"Stanisz","year":"2014","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0210","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.bbamcr.2018.05.015","article-title":"Calcium signaling and the therapeutic targeting of cancer cells","volume":"1865","author":"Bong","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ceca.2018.07.005","article-title":"CRAC channels as targets for drug discovery and development","volume":"74","author":"Stauderman","year":"2018","journal-title":"Cell Calcium"},{"key":"10.1016\/j.bbcan.2026.189548_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115955","article-title":"Orai1 Ca2+ channel modulators as therapeutic tools for treating cancer: emerging evidence!","volume":"219","author":"Mignen","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0225","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1124\/mol.105.012856","article-title":"Mechanism of inhibition of TRPC cation channels by 2-Aminoethoxydiphenylborane","volume":"68","author":"Lievremont","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0230","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-34891-7_10","article-title":"2-Aminoethoxydiphenyl borate as a common activator of TRPV1, TRPV2, and TRPV3 channels","volume":"173\u2013187","author":"Colton","year":"2007","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0235","doi-asserted-by":"crossref","first-page":"31348","DOI":"10.1074\/jbc.M804942200","article-title":"Sustained activation of the tyrosine kinase Syk by antigen in mast cells requires local Ca2+ influx through Ca2+ release-activated Ca2+ channels*","volume":"283","author":"Ng","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189548_bb0240","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1007\/s00018-018-2904-y","article-title":"Pharmacological inhibition of store-operated calcium entry in MDA-MB-468 basal A breast cancer cells: consequences on calcium signalling, cell migration and proliferation","volume":"75","author":"Azimi","year":"2018","journal-title":"Cell Mol. Life Sci. CMLS"},{"key":"10.1016\/j.bbcan.2026.189548_bb0245","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.chembiol.2014.08.016","article-title":"Identification of Orai1 channel inhibitors by using minimal functional domains to screen small molecule microarrays","volume":"21","author":"Sadaghiani","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0250","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fmolb.2022.1041674","article-title":"Orai1-mediated store-operated Ca2+ entry promotes cervical cancer progression through IL-6 signaling","volume":"9","author":"Pan","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bbcan.2026.189548_bb0255","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.112.202788","article-title":"Generation and characterization of fully human monoclonal antibodies against human Orai1 for autoimmune disease","volume":"345","author":"Lin","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbcan.2026.189548_bb0260","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1096\/fba.2020-00008","article-title":"Anti-ORAI1 antibody DS-2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T-cell and mast cell activation","volume":"2","author":"Aki","year":"2020","journal-title":"FASEB BioAdv."},{"key":"10.1016\/j.bbcan.2026.189548_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082944","article-title":"Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function","volume":"8","author":"Cox","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189548_bb0270","doi-asserted-by":"crossref","first-page":"B128","DOI":"10.1158\/1535-7163.TARG-17-B128","article-title":"Abstract B128: efficacy of RP4010, a calcium release-activated calcium (CRAC) inhibitor, in preclinical models of DLBCL","volume":"17","author":"Viswanadha","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189548_bb0275","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.canlet.2018.06.006","article-title":"Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma","volume":"432","author":"Cui","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189548_bb0280","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/cancers12030750","article-title":"Calcium release-activated calcium (CRAC) channel inhibition suppresses pancreatic ductal adenocarcinoma cell proliferation and patient-derived tumor growth","volume":"12","author":"Khan","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189548_bb0285","first-page":"569","article-title":"Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers","volume":"56","author":"Kohn","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0290","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ejca.2011.06.050","article-title":"Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole","volume":"48","author":"Ju","year":"2012","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.bbcan.2026.189548_bb0295","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1200\/JCO.2003.04.136","article-title":"Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer","volume":"21","author":"Hussain","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0300","first-page":"2324","article-title":"A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer","volume":"5","author":"Bauer","year":"1999","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0305","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1200\/JCO.2017.76.9992","article-title":"Multicenter phase IB trial of carboxyamidotriazole orotate and temozolomide for recurrent and newly diagnosed glioblastoma and other anaplastic gliomas","volume":"36","author":"Omuro","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0310","series-title":"An Open-Label, Dose-Response Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS)","author":"CalciMedica, Inc","year":"2021"},{"key":"10.1016\/j.bbcan.2026.189548_bb0315","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1113\/JP277856","article-title":"The Orai Ca2+ channel inhibitor CM4620 targets both parenchymal and immune cells to reduce inflammation in experimental acute pancreatitis","volume":"597","author":"Waldron","year":"2019","journal-title":"J. Physiol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0320","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167645","article-title":"Orai1 calcium channel inhibition prevents progression of chronic pancreatitis","volume":"8","author":"Szab\u00f3","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2026.189548_bb0325","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41418-017-0007-1","article-title":"Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: the p53 connection","volume":"25","author":"Hasna","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189548_bb0330","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202213104","article-title":"ORAI3 is dispensable for store-operated Ca2+ entry and immune responses by lymphocytes and macrophages","volume":"154","author":"Wang","year":"2022","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158020","article-title":"Isoform-specific properties of Orai homologues in activation, downstream signaling, physiology and pathophysiology","volume":"22","author":"Tiffner","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189548_bb0340","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2019.07.010","article-title":"Nanocarrier-based systems for targeted and site specific therapeutic delivery","volume":"144","author":"Majumder","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2026.189548_bb0345","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jid.2014.418","article-title":"Epigenetic changes of EGFR have an important role in BRAF inhibitor\u2013resistant cutaneous melanomas","volume":"135","author":"Wang","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0350","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI78954","article-title":"Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma","volume":"125","author":"Kwong","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189548_bb0355","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189548_bb0360","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/jid.2015.105","article-title":"MITF modulates therapeutic resistance through EGFR signaling","volume":"135","author":"Ji","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0365","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189548_bb0370","doi-asserted-by":"crossref","first-page":"462","DOI":"10.15252\/embj.201592081","article-title":"Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP \/ TAZ activation","volume":"35","author":"Kim","year":"2016","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2026.189548_bb0375","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1111\/febs.17272","article-title":"EGF\/EGFR-YAP1\/TEAD2 signaling upregulates STIM1 in vemurafenib resistant melanoma cells","volume":"291","author":"Bai","year":"2024","journal-title":"FEBS J."},{"key":"10.1016\/j.bbcan.2026.189548_bb0380","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"M\u00fcller","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189548_bb0385","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1038\/s41467-023-42239-w","article-title":"Androgen receptor is a determinant of melanoma targeted drug resistance","volume":"14","author":"Samarkina","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189548_bb0390","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1038\/s41388-022-02400-z","article-title":"Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors","volume":"41","author":"Dieter","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189548_bb0395","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","author":"Lin","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189548_bb0400","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201445","article-title":"Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma","volume":"5","author":"Romano","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.bbcan.2026.189548_bb0405","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.20892\/j.issn.2095-3941.2020.0294","article-title":"PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas","volume":"19","author":"Shen","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bbcan.2026.189548_bb0410","doi-asserted-by":"crossref","first-page":"36168","DOI":"10.18632\/oncotarget.8786","article-title":"SK3\/TRPC1\/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline","volume":"7","author":"Gu\u00e9guinou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189548_bb0415","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ceca.2010.05.002","article-title":"Coupling of mitochondria to store-operated Ca2+\u2212signaling sustains constitutive activation of protein kinase B\/Akt and augments survival of malignant melanoma cells","volume":"47","author":"Feldman","year":"2010","journal-title":"Cell Calcium"},{"key":"10.1016\/j.bbcan.2026.189548_bb0420","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202411203","article-title":"STIM-IP3R crosstalk regulates migration of breast cancer cells","volume":"224","author":"Militsin","year":"2025","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0425","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1128\/MCB.01500-14","article-title":"Novel protein kinase C-mediated control of Orai1 function in invasive melanoma","volume":"35","author":"Hooper","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0430","doi-asserted-by":"crossref","first-page":"17333","DOI":"10.1074\/jbc.M800107200","article-title":"Lipid rafts determine clustering of STIM1 in endoplasmic reticulum-plasma membrane junctions and regulation of store-operated Ca2+ entry (SOCE)","volume":"283","author":"Pani","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189548_bb0435","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/carcin\/bgn146","article-title":"Targeting lipid rafts inhibits protein kinase B by disrupting calcium homeostasis and attenuates malignant properties of melanoma cells","volume":"29","author":"Fedida-Metula","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2026.189548_bb0440","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/carcin\/bgs021","article-title":"Lipid rafts couple store-operated Ca 2+ entry to constitutive activation of PKB\/Akt in a Ca 2+ \/calmodulin-, Src- and PP2A-mediated pathway and promote melanoma tumor growth","volume":"33","author":"Fedida-Metula","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2026.189548_bb0445","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4161\/cc.20543","article-title":"Calcium\/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation","volume":"11","author":"Salzano","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2026.189548_bb0450","doi-asserted-by":"crossref","first-page":"45101","DOI":"10.1074\/jbc.M305355200","article-title":"Calcium\/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation","volume":"278","author":"Illario","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189548_bb0455","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/ncomms4183","article-title":"Distinct Orai-coupling domains in STIM1 and STIM2 define the Orai-activating site","volume":"5","author":"Wang","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189548_bb0460","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.224923","article-title":"Imaging elemental events of store-operated Ca(2+) entry in invading cancer cells with plasmalemmal targeted sensors","volume":"132","author":"Lu","year":"2019","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbcan.2026.189548_bb0465","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1158\/1078-0432.CCR-19-2773","article-title":"Targeting extracellular matrix remodeling restores BRAF inhibitor sensitivity in BRAFi-resistant melanoma","volume":"26","author":"Marusak","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0470","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2019.12.003","article-title":"Myosin II reactivation and cytoskeletal remodeling as a hallmark and a vulnerability in melanoma therapy resistance","volume":"37","author":"Orgaz","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0475","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma","volume":"6","author":"Kim","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0480","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040094","article-title":"The hippo pathway: immunity and cancer","volume":"10","author":"Taha","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189548_bb0485","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2026.189548_bb0490","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.celrep.2016.05.023","article-title":"STING pathway activation stimulates potent immunity against acute myeloid Leukemia","volume":"15","author":"Curran","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189548_bb0495","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-16-1404","article-title":"Recurrent loss of STING Signaling in melanoma correlates with susceptibility to viral oncolysis","volume":"76","author":"Xia","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0500","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/2326-6066.CIR-19-0229","article-title":"STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity","volume":"7","author":"Falahat","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0505","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbcan.2026.189548_bb0510","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.bbcan.2026.189548_bb0515","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2013598118","article-title":"Epigenetic reprogramming of tumor cell\u2013intrinsic STING function sculpts antigenicity and T cell recognition of melanoma","volume":"118","author":"Falahat","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbcan.2026.189548_bb0520","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41467-023-37217-1","article-title":"Epigenetic state determines the in vivo efficacy of STING agonist therapy","volume":"14","author":"Falahat","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189548_bb0525","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41590-018-0287-8","article-title":"The Ca2+ sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum","volume":"20","author":"Srikanth","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103314","article-title":"A STING antagonist modulating the interaction with STIM1 blocks ER-to-Golgi trafficking and inhibits lupus pathology","volume":"66","author":"Prabakaran","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.bbcan.2026.189548_bb0535","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41590-018-0300-2","article-title":"STIM1 moonlights as an anchor for STING","volume":"20","author":"Wu","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0540","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/febs.14608","article-title":"Endoplasmic reticulum stress signalling \u2013 from basic mechanisms to clinical applications","volume":"286","author":"Almanza","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.bbcan.2026.189548_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113741","article-title":"Endoplasmic reticulum stress in melanoma pathogenesis and resistance","volume":"155","author":"Kong","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189548_bb0550","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.3390\/cancers13143498","article-title":"Autophagy inhibition in BRAF-driven cancers","volume":"13","author":"Foth","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189548_bb0555","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.cell.2016.12.004","article-title":"Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer","volume":"168","author":"Cubillos-Ruiz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0560","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/cdd.2014.183","article-title":"Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma","volume":"22","author":"Corazzari","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189548_bb0565","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003057","article-title":"Vemurafenib potently induces endoplasmic reticulum stress\u2013mediated apoptosis in BRAFV600E melanoma cells","volume":"6","author":"Beck","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbcan.2026.189548_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113540","article-title":"The ER stress sensor IRE1 interacts with STIM1 to promote store-operated calcium entry, T cell activation, and muscular differentiation","volume":"42","author":"Carreras-Sureda","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189548_bb0575","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcancer.2019.11.007","article-title":"Regulation of autophagy by canonical and non-canonical ER stress responses","volume":"66","author":"Bhardwaj","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0580","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1172\/JCI70454","article-title":"Targeting ER stress\u2013induced autophagy overcomes BRAF inhibitor resistance in melanoma","volume":"124","author":"Ma","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189548_bb0585","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-0560.2009.01359.x","article-title":"Autophagy in cutaneous malignant melanoma","volume":"37","author":"Lazova","year":"2010","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0590","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1158\/1078-0432.CCR-10-2372","article-title":"Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma","volume":"17","author":"Ma","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0595","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3892\/or.2018.6430","article-title":"Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment","volume":"40","author":"Ryabaya","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189548_bb0600","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1703921114","article-title":"Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner","volume":"114","author":"Mgrditchian","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbcan.2026.189548_bb0605","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s13577-017-0167-9","article-title":"Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells","volume":"30","author":"Sun","year":"2017","journal-title":"Hum. Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0610","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/jcmm.13029","article-title":"Inhibition of Orai1-mediated Ca2+ entry enhances chemosensitivity of HepG2 hepatocarcinoma cells to 5-fluorouracil","volume":"21","author":"Tang","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189548_bb0615","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2019.4696","article-title":"Mitochondrial calcium: transport and modulation of cellular processes in homeostasis and cancer (review)","author":"Romero-Garcia","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0620","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molcel.2006.12.009","article-title":"Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2","volume":"25","author":"H\u00f8yer-Hansen","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0625","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.2147\/OTT.S262022","article-title":"AMPK\/mTOR\/ULK1 Axis-mediated pathway participates in apoptosis and autophagy induction by oridonin in colon cancer DLD-1 cells","volume":"13","author":"Bu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bbcan.2026.189548_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2022.102551","article-title":"The STIM1 phosphorylation Saga","volume":"103","author":"Yu","year":"2022","journal-title":"Cell Calcium"},{"key":"10.1016\/j.bbcan.2026.189548_bb0635","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cophys.2020.07.007","article-title":"STIM proteins at the intersection of signaling pathways","volume":"17","author":"Poth","year":"2020","journal-title":"Curr. Opin. Physio."},{"key":"10.1016\/j.bbcan.2026.189548_bb0640","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.ads6550","article-title":"Loss of STIM2, but not of STIM1, drives colorectal cancer metastasis through metabolic reprogramming and the ATF4 ER stress pathway","volume":"18","author":"Pathak","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbcan.2026.189548_bb0645","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1016\/j.jid.2021.03.031","article-title":"The XBP1\u2013MARCH5\u2013MFN2 Axis confers endoplasmic reticulum stress resistance by coordinating mitochondrial fission and mitophagy in melanoma","volume":"141","author":"Wang","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114104","article-title":"Targeting mitochondria in melanoma: interplay between MAPK signaling pathway and mitochondrial dynamics","volume":"178","author":"Ferraz","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0655","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.molcel.2015.01.003","article-title":"Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors","volume":"57","author":"Serasinghe","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0660","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/jid.2015.196","article-title":"Activation of the mitochondrial fragmentation protein DRP1 correlates with BRAFV600E melanoma","volume":"135","author":"Wieder","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0665","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-025-00836-5","article-title":"Endoplasmic reticulum stress responses in anticancer immunity","author":"Hwang","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189548_bb0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","article-title":"How the Warburg effect supports aggressiveness and drug resistance of cancer cells?","volume":"38","author":"Icard","year":"2018","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2026.189548_bb0675","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","article-title":"100 years of the Warburg effect: a cancer metabolism endeavor","volume":"187","author":"Fendt","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0680","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1113\/JP278810","article-title":"Revisiting the Warburg effect: historical dogma versus current understanding","volume":"599","author":"Vaupel","year":"2021","journal-title":"J. Physiol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0685","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.canlet.2020.12.021","article-title":"The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment","volume":"500","author":"Hayes","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189548_bb0690","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"De La Cruz-L\u00f3pez","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0695","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3389\/fonc.2020.00722","article-title":"Metabolic plasticity of melanoma cells and their crosstalk with tumor microenvironment","volume":"10","author":"Avagliano","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189548_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111873","article-title":"The role of hypoxia-inducible factor-1alpha and its signaling in melanoma","volume":"141","author":"Malekan","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189548_bb0705","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202051436","article-title":"MAPK signaling regulates c-MYC for melanoma cell adaptation to asparagine restriction","volume":"22","author":"Pathria","year":"2021","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbcan.2026.189548_bb0710","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189548_bb0715","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/pcmr.12661","article-title":"Metabolic strategies of melanoma cells: mechanisms, interactions with the tumor microenvironment, and therapeutic implications","volume":"31","author":"Fischer","year":"2018","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2026.189548_bb0720","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1476-4598-11-76","article-title":"Importance of glycolysis and oxidative phosphorylation in advanced melanoma","volume":"11","author":"Ho","year":"2012","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189548_bb0725","first-page":"1","article-title":"Autophagy, Warburg, and Warburg reverse effects in human Cancer","volume":"2014","author":"Gonzalez","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbcan.2026.189548_bb0730","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41416-020-01159-y","article-title":"Mitochondrial oxidative phosphorylation in cutaneous melanoma","volume":"124","author":"Kumar","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189548_bb0735","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41419-018-0340-4","article-title":"Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors","volume":"9","author":"Khamari","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189548_bb0740","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.18632\/oncotarget.1420","article-title":"Mitochondrial oxidative stress is the achille\u2019s heel of melanoma cells resistant to Braf-mutant inhibitor","volume":"4","author":"Corazao-Rozas","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189548_bb0745","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/1535-7163.MCT-16-0068","article-title":"The BRAF inhibitor vemurafenib activates mitochondrial metabolism and inhibits hyperpolarized pyruvate-lactate exchange in BRAF-mutant human melanoma cells","volume":"15","author":"Delgado-Goni","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189548_bb0750","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021110046","article-title":"Suppression of Ca2+ signaling enhances melanoma progression","volume":"41","author":"Gross","year":"2022","journal-title":"EMBO J."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2600020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2600020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:36:50Z","timestamp":1782031010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X2600020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X2600020X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189548","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting store-operated Ca2+ entry as a novel strategy to overcome treatment resistance in melanoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189548"}}